Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Ciliary dyskinesia, Hearing loss (hearing impairment), Bronchiectasis, and Reduced forced vital capacity and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Ears | 2 | Hearing loss (hearing impairment), Recurrent otitis media |
STK36 function has not been fully characterized.
Ciliary dyskinesia, primary, 46 has been associated with mutations in the STK36 gene on chromosome 2.
Genetic testing for STK36 is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for ciliary dyskinesia, primary, 46 has been reported in the published literature.
Phenotype severity distribution: 9 always present features.
No clinical trials have been registered for ciliary dyskinesia, primary, 46.
20 publications have been identified in PubMed for ciliary dyskinesia, primary, 46. Research spans Epidemiology / Natural History (25%), Diagnostic / Biomarker (20%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 5 | 25% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:21 PM UTC
Online Mendelian Inheritance in Man
Common questions about ciliary dyskinesia, primary, 46
2 |
Bronchiectasis, Recurrent pneumonia |
Brain and nerves | 1 | Ciliary dyskinesia |
Testing and diagnosis research
4 |
20% |
Patient case studies | 4 | 20% |
Research summaries | 3 | 15% |
Laboratory research | 2 | 10% |
Clinical study results | 1 | 5% |
New treatment approaches | 1 | 5% |
Haarman EG (2026). [PMID: 41928691](https://pubmed.ncbi.nlm.nih.gov/41928691/). *Pediatr Pulmonol*. [Review / Meta-Analysis]
O'Brien Á (2026). [PMID: 41883896](https://pubmed.ncbi.nlm.nih.gov/41883896/). *Cureus*. [Case Report / Case Series]
Ito M (2026). [PMID: 41062319](https://pubmed.ncbi.nlm.nih.gov/41062319/). *Intern Med*. [Case Report / Case Series]
Ito M (2026). [PMID: 41570615](https://pubmed.ncbi.nlm.nih.gov/41570615/). *Respir Investig*. [Epidemiology / Natural History]
Chen SC (2026). [PMID: 42083040](https://pubmed.ncbi.nlm.nih.gov/42083040/). *J Biomed Sci*. [Review / Meta-Analysis]
Batu U (2026). [PMID: 41837195](https://pubmed.ncbi.nlm.nih.gov/41837195/). *Front Pediatr*. [Diagnostic / Biomarker]
Karakoç E (2025). [PMID: 40142748](https://pubmed.ncbi.nlm.nih.gov/40142748/). *J Clin Med*. [Diagnostic / Biomarker]
Briggs L (2025). [PMID: 40758541](https://pubmed.ncbi.nlm.nih.gov/40758541/). *Am J Respir Crit Care Med*. [Diagnostic / Biomarker]
Choi H (2025). [PMID: 39490969](https://pubmed.ncbi.nlm.nih.gov/39490969/). *Chest*. [Diagnostic / Biomarker]
Amuzie C (2025). [PMID: 40898803](https://pubmed.ncbi.nlm.nih.gov/40898803/). *Ophthalmic Genet*. [Case Report / Case Series]